Joubert-Boltshauser syndrome; Joubertsyndrome related disorders (JSRD), including: Cerebellar vermishypoplasia/aplasia, oligophrenia, congenital ataxia, ocular coloboma,and hepatic fibrosis (COACH) syndrome; Cerebellooculorenal orcerebello-oculo-renal (COR) syndrome; Dekaban–Arima syndrome;Va´radi–Papp syndrome or orofaciodigital type VI (OFDVI) syndrome;Malta syndrome.1.2 OMIM# of the disease213300, 243910, 216360, and 277170.1.3 Name of the analysed genes or DNA/chromosome segmentsJBTS1/INPP5E, JBTS2/TMEM216, JBTS3/AHI1, JBTS4/NPHP1,JBTS5/CEP290, JBTS6/TMEM67, JBTS7/RPGRIP1L, JBTS8/ARL13B,JBTS9/CC2D2A, and JBTS10/OFD1.1.4 OMIM# of the gene(s)613037, 613277, 608894, 607100, 610142, 609884, 610937, 608922,612013, and 300170.1.5 Mutational spectrumMissense and nonsense mutations, splice site mutations, deletions,and insertions. Genomic rearrangements so far reported onlyfor NPHP1 (homozygous deletions represent 495% mutations)and CEP290 (heterozygous multiexon deletion reported in asingle patient). Marked allelic heterogeneity, with a large numberof mutations, was reported in each of the 10 genes. Gene–phenotype correlations are known for selected genes (about 50%patients with COR phenotype and about 75% patients withCOACH phenotype have mutations in CEP290 and TMEM67 genes,respectively).1.6 Analytical methodsDirect sequencing of coding genomic regions and splice site junctions;multiplex microsatellite analysis for detection of NPHP1 homozygousdeletion. Possibly, qPCR or targeted array-CGH for detection ofgenomic rearrangements in other genes.1.7 Analytical validationDirect sequencing of both DNA strands; verification of sequence andqPCR results in an independent experiment.1.8 Estimated frequency of the disease(incidence at birth (‘birth prevalence’) or population prevalence)No good population-based data on JSRD prevalence have beenpublished. A likely underestimated frequency between 1/80000 and1/100000 live births is based on unpublished data.1.9 If applicable, prevalence in the ethnic group of investigatedpersonIn Ashkenazi Jews, the estimated carrier frequency of the foundermutation p.R73L in the TMEM216 gene is about 1%.1.10 Diagnostic settingComment: The early detection of breathing abnormalities and/oroculomotor apraxia is suggestive of JS and related disorders. Definitediagnosis is made based on the identification of the characteristichindbrain malformation on brain imaging, that is, the ‘molar toothsign’ or its component features.2. TEST CHARACTERISTICS2.1 Analytical sensitivity(proportion of positive tests if the genotype is present)Nearly 100%. A test for large deletions/duplications in genes otherthan NPHP1 should be considered, especially in patients in whom asingle heterozygous mutation has been detected with conventionalsequencing. The presence of deep intronic mutations is not exploredwith current screening methods.
Read full abstract